Crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole, preparation method therefor and pharmaceutical composition thereof

Galunisertib Form 1 having the structure shown in formula (I) below,

• wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the galunisertib Form 1, has the following characteristic peaks:
• 10.2°±0.2°, 14.6°±0.2°, 15.8°±0.2°, 19.0°±0.2°, 19.4°±0.2°, and 21.9°±0.2°.

Galunisertib Form 2 having the structure shown in formula (I) below,

• wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the galunisertib Form 1, has the following characteristic peaks:
• 7.9°±0.2°, 11.7°±0.2°, 12.9°±0.2°, 14.7°±0.2°, 20.5°±0.2°, and 21.9°±0.2°.

Galunisertib Form 3 having the structure shown in formula (I) below,

• wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the galunisertib Form 3, has the following characteristic peaks:
• 8.6°±0.2°, 12.3°±0.2°, 14.5°±0.2°, 17.9°±0.2°, 19.4°±0.2°, and 21.0°±0.2°.

Galunisertib Form 4 having the structure shown in formula (I) below,

• wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the galunisertib Form 4, has the following characteristic peaks:
• 5.9°±0.2°, 11.7°±0.2°, 12.2°±0.2°, 14.1°±0.2°, 16.4°±0.2°, and 21.8°±0.2°.

Galunisertib Form 7 having the structure shown in formula (I) below,

• wherein the galunisertib Form 7 has 0.5 to 1.0 mole of water, and wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the galunisertib Form 7, has the following characteristic peaks:
• 7.0°±0.2°, 8.6°±0.2°, 14.2°±0.2°, 16.7°±0.2°, 21.4°±0.2°, and 23.4°±0.2°.